Shares of Vectura Group PLC (LON:VEC) have earned a consensus rating of “Buy” from the seven brokerages that are covering the company, MarketBeat Ratings reports. Three research analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 1 year price target among brokers that have covered the stock in the last year is GBX 125.75 ($1.64).
Several analysts have recently commented on the stock. Shore Capital restated a “hold” rating on shares of Vectura Group in a research note on Tuesday, March 26th. Peel Hunt reduced their target price on shares of Vectura Group from GBX 107 ($1.40) to GBX 105 ($1.37) and set a “hold” rating for the company in a research note on Tuesday, March 12th. Morgan Stanley restated a “buy” rating and issued a GBX 160 ($2.09) target price on shares of Vectura Group in a research note on Friday, May 24th. Finally, Numis Securities restated a “buy” rating and issued a GBX 160 ($2.09) target price on shares of Vectura Group in a research note on Wednesday, May 8th.
LON:VEC traded down GBX 3.55 ($0.05) during trading hours on Tuesday, reaching GBX 80.45 ($1.05). 2,426,113 shares of the company’s stock were exchanged, compared to its average volume of 4,610,000. The stock has a market cap of $534.09 million and a P/E ratio of -6.09. The company has a debt-to-equity ratio of 0.81, a current ratio of 2.35 and a quick ratio of 1.90. Vectura Group has a 1-year low of GBX 65.85 ($0.86) and a 1-year high of GBX 90.15 ($1.18).
Vectura Group plc engages in the design, development, and supply of pharmaceutical products for the treatment of airways-related diseases worldwide. The company's in-market products include Seebri Breezhaler and Neohaler, a DPI device and bronchodilator; AirFluSal Forspiro for the treatment of asthma and chronic obstructive pulmonary disease (COPD); Breelib for the treatment of pulmonary arterial hypertension; Relvar Ellipta/Breo Ellipta that is used in treating asthma and COPD; and Incruse Ellipta and Anoro Ellipta for the treatment of COPD.
Featured Article: The components of the Stochastic Momentum Index
Receive News & Ratings for Vectura Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vectura Group and related companies with MarketBeat.com's FREE daily email newsletter.